Published in final edited form as:

Chem Res Toxicol. 2014 February 17; 27(2): 304–308. doi:10.1021/tx4004374.

Thalidomide Increases Human Hepatic Cytochrome P450 3A Enzymes by Direct Activation of Pregnane X Receptor

Norie Murayama^{#1}, Rinie van Beuningen^{#2}, Hiroshi Suemizu³, Christiane Guguen Guillouzo⁴, Norio Shibata⁵, Kanako Yajima¹, Masahiro Utoh¹, Makiko Shimizu¹, Christophe Chesné⁴, Masato Nakamura³, F. Peter Guengerich⁶, René Houtman^{2,*}, and Hiroshi Yamazaki^{1,*}

¹Showa Pharmaceutical University, Machida, Japan ²PamGene International, Den Bosch, Netherlands ³Central Institute for Experimental Animals, Kawasaki, Japan ⁴Biopredic International, Rennes, France ⁵Nagoya Institute of Technology, Nagoya, Japan ⁶Vanderbilt University School of Medicine, Nashville, TN, USA

[#] These authors contributed equally to this work.

Abstract

Heterotropic cooperativity of human cytochrome P450 (P450) 3A4/3A5 by the teratogen thalidomide was recently demonstrated by H. Yamazaki et al. (2013) using the model substrate midazolam in various *in vitro* and *in vivo* models. Chimeric mice with humanized liver also displayed enhanced midazolam clearance upon pre treatment with orally administered thalidomide, presumably because of human P450 3A induction. In the current study, we further investigated the regulation of human hepatic drug metabolizing enzymes. Thalidomide enhanced levels of P450 3A4 and 2B6 mRNA, protein expression, and/or oxidation activity in human hepatocytes, indirectly suggesting activation of upstream transcription factors involved in detoxication, e.g. the nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR). A key event after ligand binding is an alteration of nuclear receptor conformation and recruitment of co regulator proteins that alter chromatin accessibility of target genes. To investigate direct engagement and functional alteration of PXR and CAR by thalidomide, we utilized a peptide microarray with 154 co regulator derived nuclear receptor interaction motifs and co regulator and nuclear receptor boxes, which serves as a sensor for nuclear receptor conformation and activity status as a function of ligand. Thalidomide and its human proximate metabolite 5 hydroxythalidomide displayed significant modulation of co regulator interaction with PXR and CAR ligand binding domains, similar to established agonists for these receptors. These results collectively suggest that thalidomide acts as a ligand for PXR and CAR and causes enzyme induction leading to increased P450 enzyme activity. The possibilities of drug interactions during thalidomide therapy in humans require further evaluation.

* Correspondence to (H.Y.) Showa Pharmaceutical University, 3 3165 Higashi tamagawa Gakuen, Machida, Tokyo 194 8543, Japan. Telephone: +81 42 721 1406; FAX: +81 42 721 1406. hyamazak@ac.shoyaku.ac.jp. (R.H.) PamGene International, Den Bosch, Netherlands. Telephone: +31 73 6158932. rhoutman@pamgene.com.

Supporting Information

This material is available free of charge via the Internet at <http://pubs.acs.org>.

Introduction

The sedative drug thalidomide [α (*N* phthalimido)glutarimide] was withdrawn in the early 1960s due to its potent teratogenic effects¹ but it was subsequently approved for the treatment of multiple myeloma.^{2,3} Because of the recent emergence of thalidomide as a drug with clinical potential, there is renewed interest in both its toxicity and pharmacological mechanisms. Various hypotheses (for both) have been proposed, including generation of reactive oxygen species,⁴ generation of reactive acylating⁵ and arene oxide intermediates,⁶ inhibition of angiogenesis,⁷ and inhibition of the protein cereblon.⁸ Two analogs of thalidomide with increased potency and reduced toxicity, lenalidomide and pomalidomide, have also entered the clinic for the treatment of refractory multiple myeloma.⁹

The teratogenicity of thalidomide is species specific and occurs in primates but not in rats and mice. The mechanism of action of thalidomide still remains unclear, but it has been shown that metabolism of thalidomide is important for both teratogenicity and cancer treatment outcome. We previously reported cooperativity of human P450 subfamily 3A enzymes for thalidomide¹⁰ and 5 hydroxy product formation from thalidomide (Figure 1) mediated by human P450 3A4.^{11,12} Also, the second oxidation step involves a reactive intermediate, possible an arene oxide that can be trapped by GSH to give GSH adducts.¹³ Two aspects of *in vivo* drug interaction of thalidomide were reported:¹⁴ an enhanced clearance of midazolam and a higher area under the curve of 4 hydroxymidazolam following pre treatment with thalidomide in humanized liver mice, presumably due to human P450 3A induction. Although induction of total P450 contents by thalidomide in rat livers have been reported,¹⁵ apparently no interaction of thalidomide has been shown with ethinyl estradiol (P450 3A4 substrate and inhibitor) in humans.¹⁶ *In vivo* cooperativity of human P450 3A enzymes was also reported as another aspect, with a higher area under the curve for 1'-hydroxymidazolam following co treatment with thalidomide in the humanized mice.¹⁴ It is important to evaluate any drug interactions through human P450 enzymes by concomitant thalidomide therapy using the basic research technique.

To clarify the potential of thalidomide, a microarray assay for real time co regulator nuclear receptor interaction (MARCoNI) was adopted for investigating P450 induction by thalidomide and 5 hydroxythalidomide, one of the metabolites formed by human P450 subfamily 3A enzymes, plus 5'-hydroxythalidomide, a major product formed by rodents (Figure 1) in the present study. We report here that thalidomide can act as an agonist for pregnane X receptor (PXR) and cause P450 3A enzyme induction.

MATERIALS AND METHODS

Chemicals and Cells

(*R*) (+)-Thalidomide, rifampicin, dexamethasone, RU486 (Sigma Aldrich, St. Louis, MO), pomalidomide (Selleck Chemicals, Houston, TX), and GSH transferase (GST) tagged human ligand binding PXR and constitutive androstane receptor (CAR) domains (LBD GST, PV4841 and PV4838, respectively, Invitrogen, Breda, Netherlands) were purchased from the indicated sources. 5 Hydroxy and 5'-hydroxythalidomide were synthesized as reported previously.¹⁷ Polyclonal anti human P450 3A4 antibodies were obtained from BD

Biosciences (San Jose, CA). Other chemicals and reagents used in this study were obtained from the sources described previously¹⁴ or were of the highest quality commercially available.

Cryopreserved differentiated HepaRG cells (Biopredic International, Rennes, France) and human hepatocytes (BD Biosciences) were plated in collagen coated 24 well plates according to these manufacturer's instructions. After plating, the differentiated HepaRG cells were maintained for 72 h (at 37 °C, 5% CO₂, v/v) in the general purpose supplement ADD670. At the incubation, medium was aspirated and replaced with a serum free induction medium, which included induction supplement 650 (ADD650). Thalidomide and its metabolites were added in the medium on each concentration. The medium was replaced every 24 h and each chemical was added for 48 or 72 h.

Measurements of Catalytic Activities, Protein, and mRNA of P450s in Cells

After incubation with thalidomide and its metabolites, the culture medium was aspirated. The cells were rinsed twice with pre warmed phosphate buffered saline and was incubated at 37 °C in 5% CO₂ (v/v) with serum free incubation medium containing midazolam (50 µM) and bupropione (100 µM) for 3 h. After the incubation, the reaction was stopped by adding an equal volume of ice cold CH₃OH containing the internal standard caffeine (100 µM). The samples were centrifuged at $10^4 \times g$ for 5 min and the supernatant was collected for metabolite analysis. A Quattro Micro API mass analyzer (Waters, Tokyo, Japan) was used, directly coupled to a Waters LC 2695 system with an octadecylsilane (C₁₈) column (Atlantis, 3 µm, 2.1 mm × 50 mm), with MassLynx NT4.1 software used for data acquisition (Waters). Measurements of 1' and 4 hydroxymidazolam were performed in the electrospray positive ionization mode as described previously,¹⁴ and 1' hydroxymidazolam *O* and *N* glucuronides were monitored using multiple reaction monitoring mode of the transition m/z 518 → m/z 324. Bupropione hydroxylation activities were determined using the same LC/MS conditions but with different molecular mass. The metabolites were quantified using the m/z 342 → 325 transition for hydroxybupropione and the m/z 195 → 138 transition of the internal standard caffeine, respectively.

After measurements of drug oxidation activities, the cells were washed with 500 µL of phosphate buffered saline twice and were collected by centrifugation (at $2 \times 10^4 \times g$ for 3 min). Cell lysis buffer (30 µL) was added to the suspended cells. After freezing and thawing, the cell supernatants were collected following centrifugation (at $1.1 \times 10^4 \times g$ for 15 min). Cell lysates were analyzed for protein content using Pierce BCA protein analysis reagent and used for SDS polyacrylamide gel electrophoresis and immunoblotting with anti human P450 antibodies. The specific protein P450 3A4/5 was detected by using an ECL detection kit (GE Healthcare, Buckinghamshire, UK).

After incubation of human hepatocytes or HepaRG cells with thalidomide and its metabolites, total RNA was also extracted from with use of an Qiagen Rneasy mini kit according to the manufacturer's instructions. Levels of mRNA of human P450 2B6 (Hs04183483_g1) and 3A4 mRNA (Hs01546612_m1) were determined with the use of a TaqMan expression quantitative polymerase chain reaction according to the manufacturer's

protocol. The relative P450 expression levels were estimated following normalization for the levels of GAPDH (Hs99999905_m1) in three independent amplifications.

Microarray Assay for Real-time Analysis of Co-regulator–Nuclear Receptor

Interaction (MARCoNI)

Ligand-modulated interaction of co-regulators with PXR and CAR was assessed using a PamChip peptide microarray containing 154 unique co-regulator motifs (#88101, PamGene International BV, Den Bosch, Netherlands) as described previously.¹⁸ Briefly, all incubations were performed at 20°C on a PamStation®-96 (PamGene), using two cycles per minute. Assay mixtures contained 5 nM PXR or CAR (glutathione S transferase tagged ligand binding domain), 25 nM Alexa488-conjugated GST antibody (A11131, Invitrogen), 0.1 mM thalidomide or its metabolites, dexamethasone, rifampicin, or RU486 in 'TR-FRET PXR Assay Buffer' or 'TR-FRET Coregulator Buffer G' (PV4842, PV4553 resp., Invitrogen) and 5 mM dithiothreitol. The complete assay mix with solvent only (DMSO, 2% final concentration, v/v), representing nuclear receptors in the apo conformation (no ligand), served as the negative control.

Each array was blocked for 20 cycles with 25 µL of 1% bovine serum albumin (w/v) and 0.01% Tween20 (w/v) in Tris buffered saline. Next, the blocking buffer was removed by aspiration and each array was incubated for 80 cycles with 25 µL of each assay mix. Subsequently, unbound ligand/receptor was removed by washing of the arrays with 25 µL of Tris buffered saline, and finally a tiff image each array was acquired by the CCD camera of the PamStation.

Image Analysis

The fluorescent signal of each spot in each array (representative of nuclear receptor binding to that particular co-regulator motif) was quantified using BioNavigator software (PamGene). Each tiff image (single array) was overlaid with a synthetic grid of spot sized circles. An algorithm was used to optimize placement of each circle around its respective spot (actual peptide position) on the tiff image. The median fluorescence within each circle, as well as that in a defined area surrounding the circle, was quantified. For each spot, the median signal minus background was calculated and used for further analysis.

Comparison of Responses to Compounds

Each condition was measured using four technical replicates (arrays) and thus resulted in four binding values for the compound-stimulated (or apo) nuclear receptor binding to a particular co-regulator motif. Data were analyzed and visualized using BioNavigator R version 2.15.3 (copyright© 2013, The R Foundation for Statistical Computing). Compound-mediated modulation of nuclear receptor binding to each individual co-regulator (Modulation Index, MI) was calculated as $\log_{10}$ -transformed nuclear receptor binding (fluorescence) in the presence of ligand over that in the presence of solvent only. In addition, we performed Student's t-test on nuclear receptor binding (apo vs. compound-stimulated) to assess the significance of the effect of each compound. Because each array contains 154 unique co-regulator motifs, each compound was characterized by a 154 point MI signature. Compound signatures were subjected to hierarchical clustering using

Euclidean distance and average linkage. For each receptor, compound (dis)similarities were visualized as a dendrogram of a clustered MI heat map in which significance of the modulation of each interaction is indicated (*: $p < 0.05$; **: $p < 0.01$; ***: $p < 0.001$).

RESULTS AND DISCUSSION

P450 3A Induction by Thalidomide in Human Hepatocytes and HepaRG Cells

Human hepatocytes and HepaRG cells were cultured with thalidomide and its metabolites for 72 h (Figure 2). The midazolam 4- and 1-hydroxylation activities were increased by treatment with thalidomide but not by its metabolites in human hepatocytes (Figure 2A) and HepaRG cells (Figure 2B). A low formation rate of 1-hydroxymidazolam *O*-glucuronide was enhanced 3 fold in HepaRG cells (Figure 2C). Similarly, induction of P450 2B-dependent bupropion hydroxylation activity by thalidomide was seen (Figure 2D). Under the separate experiments, P450 3A4 was induced (> 20-fold) by a positive control, rifampicin, in the hepatocytes and HepaRG cells (results not shown).

Effects of thalidomide on expression levels of P450 mRNA in human hepatocytes and HepaRG cells were examined after 48 h incubation (Figure 3). The mRNA levels of P450 3A4 and 2B6 were enhanced following exposure to increasing concentrations of thalidomide (Figure 3). The induction of P450 3A4 mRNA in hepatocytes and HepaRG cells was 2.0- and 4.5-fold, respectively. In contrast, the fold induction of P450 2B6 mRNA in hepatocytes and HepaRG cells was much less (1.2- and 1.4-fold, respectively). These results collectively indicate that thalidomide is an inducer of human P450 3A enzymes but not a potent one, as judged by the catalytic activity, protein expression, and mRNA determinations in human hepatocytes or HepaRG cells.

Protein fractions were taken from the treated cells as cell-lysates after the evaluation of catalytic function shown in Figures 2A and 2B. Induction of P450 3A protein by 1.0 mM thalidomide treatment (but not by the metabolites) 2.0-fold in both human hepatocytes and HepaRG cells was confirmed by immunoblotting with anti-human P450 3A antibodies (Figure S1, Supporting Information). These results are comparable with enhancement of catalytic activity (Figures 2A, 2B) and mRNA level (Figure 3) in human hepatocytes and HepaRG cells.

Thalidomide-induced Modulation of CAR and PXR Affinity for Co-regulator Proteins

Ligand binding by a nuclear receptor allosterically induces conformational changes and regulates interaction with co-regulator proteins. To test whether thalidomide was able to modulate CAR or PXR affinity, we applied a Microarray Assay for Real time Co-regulator-Nuclear Receptor Interaction (MARCoNI). In this assay, a set of co-regulator proteins is represented by their nuclear receptor-interacting (CoR)NR-box motifs by means of immobilized peptides. A GST-tagged ligand-binding domain of each receptor was incubated on the array in the presence or absence of each compound. Receptor binding to each motif was detected using a fluorescently-labeled GST antibody, resulting in a 154-point binding profile for each condition. These binding profiles were converted into response profiles by calculating the compound-induced $\log_{10}$ -fold modulation of binding vs. control (solvent only).

Two positive control agonists for PXR activation (Figure 4A)—dexamethasone and rifampicin—clearly modulate co regulator interaction, reflected by significant and robust attraction (red) and repulsion (blue) of particular subsets of co regulator motifs. Alternatively, RU486, another PXR agonist, shows only moderate repulsion of co-regulators, which suggests an alternative mechanism of action. To emphasize (dis)-similarity in response profiles (and mechanisms of action) between different compounds, we applied hierarchical clustering analysis. Interestingly, thalidomide and its human metabolite 5-hydroxythalidomide also strongly modulated PXR-coregulator interaction in a manner highly similar to dexamethasone and rifampicin, with some small differences in individual interactions. Thalidomide even displayed superior displacement efficacy of a series of motifs (extreme left) compared to the reference agonists, a feature that appears to be lost following conversion to 5-hydroxythalidomide. Alternatively, the rodent metabolite 5'-hydroxythalidomide seemed to lack virtually all of the modulating effect on this (human) receptor. Similarly, thalidomide and the human—but not rodent—metabolite similarly modulate co regulator interaction of human CAR, with slightly higher efficacy for thalidomide (Figure 4B). Recently we reported that pomalidomide was oxidized by human liver microsomes and P450s 2C19, 3A4, and 2J2 to the corresponding phthalimide ring hydroxylated product.¹⁹ In addition, we tested the analogues lenalidomide and pomalidomide, which displayed weak or absence of modulation. It has been recently reported that many ligands for inducing CAR are indirect—not directly binding ligands—but actually ligands for EGF receptor.²⁰

In the present study we investigated the induction of P450 3A enzymes to fully understand the metabolic activation of thalidomide. Interestingly, there was little effect of 5'-hydroxythalidomide. The auto-induction by thalidomide of human P450 3A should be associated with PXR, one of members of the steroid hormone nuclear receptor family, revealed by a novel microarray assay for real-time analysis of co-regulator-nuclear receptor interaction (MARCoNI, Figure 4). Heterodimers (e.g. RXR) with PXR could regulate expression of human P450 enzymes and/or some other enzymes such as GSTs and UDP-glucuronosyltransferase. These drug-metabolizing enzymes could have some impact on the clearance of thalidomide in humans. The apparent functional drug oxidation activities mediated by P450 3A4 and 3A5 *in vitro* and *in vivo* could be differentially observed in combination with induction and cooperativity of P450 3A4 and/or P450 3A5. In conclusion, thalidomide was capable of binding to PXR directly and induced transcriptional regulation of human P450 3A gene. Drug interactions of thalidomide should be evaluated with the knowledge that the drug and its human metabolite are P450 inducers.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Sources

This work was supported in part by the Ministry of Education, Culture, Sports, Science, and Technology of Japan and JCIA's LRI program (H.Y.) and United States Public Health Service grant R37 CA090426 (F.P.G.).

Abbreviations

CAR	constitutive androstane receptor
MARCoNI	a microarray assay for real time co regulator nuclear receptor interaction
PXR	pregnane X receptor

References

1. Speirs AL. Thalidomide and congenital abnormalities. *Lancet*. 1962; 1:303–305. [PubMed: 13915621]
2. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL. Thalidomide for treatment of multiple myeloma: 10 years later. *Blood*. 2008; 111:3968–3977. [PubMed: 18245666]
3. Nakamura K, Matsuzawa N, Ohmori S, Ando Y, Yamazaki H, Matsunaga T. Clinical evidence of the pharmacokinetics change in thalidomide therapy. *Drug Metab. Pharmacokinet.* 2013; 28:38–43. [PubMed: 23165864]
4. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. *Nat. Med.* 1999; 5:582–585. [PubMed: 10229238]
5. Fabro S, Smith RL, Williams RT. Thalidomide as a possible biological acylating agent. *Nature*. 1965; 208:1208–1209. [PubMed: 5870320]
6. Gordon GB, Spielberg SP, Blake DA, Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. *Proc. Natl. Acad. Sci. U.S.A.* 1981; 78:2545–2548. [PubMed: 6941308]
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. *Proc. Natl. Acad. Sci. U.S.A.* 1994; 91:4082–4085. [PubMed: 7513432]
8. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. *Science*. 2010; 327:1345–1350. [PubMed: 20223979]
9. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. *Leuk. Lymphoma*. 2013; 54:683–687. [PubMed: 22966948]
10. Okada Y, Murayama N, Yanagida C, Shimizu M, Guengerich FP, Yamazaki H. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. *Drug Metab. Dispos.* 2009; 37:18–23. [PubMed: 18948377]
11. Yamazaki H, Suemizu H, Igaya S, Shimizu M, Shibata M, Nakamura M, Chowdhury G, Guengerich FP. *In vivo* formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. *Chem. Res. Toxicol.* 2011; 24:287–289. [PubMed: 21299192]
12. Yamazaki H, Suemizu H, Shimizu M, Igaya S, Shibata N, Nakamura N, Chowdhury G, Guengerich FP. *In vivo* formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK NOG mice. *Chem. Res. Toxicol.* 2012; 25:274–276. [PubMed: 22268628]
13. Chowdhury G, Murayama N, Okada Y, Uno Y, Shimizu M, Shibata N, Guengerich FP, Yamazaki H. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. *Chem. Res. Toxicol.* 2010; 23:1018–1024. [PubMed: 20443640]
14. Yamazaki H, Suemizu H, Murayama N, Utoh M, Shibata N, Nakamura M, Guengerich FP. *In vivo* drug interactions of the teratogen thalidomide with midazolam: Heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. *Chem. Res. Toxicol.* 2013; 26:486–489. [PubMed: 23419139]
15. Tsambaos D, Bolsen K, Georgiou S, Monastirli A, Goerz G. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene. *Arch. Dermatol. Res.* 1994; 286:347–349. [PubMed: 7979550]

16. Scheffler MR, Colburn W, Kook KA, Thomas SD. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. *Clin. Pharmacol. Ther.* 1999; 65:483–490. [PubMed: 10340913]
17. Yamamoto T, Shibata N, Sukeguchi D, Takashima M, Nakamura S, Toru T, Matsunaga N, Hara H, Tanaka M, Obata T, Sasaki T. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides. *Bioorg. Med. Chem. Lett.* 2009; 19:3973–3976. [PubMed: 19297157]
18. Houtman R, de Leeuw R, Rondaij M, Melchers D, Verwoerd D, Ruijtenbeek R, Martens JW, Neefjes J, Michalides R. Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. *Mol. Cancer Ther.* 2012; 11:805–816. [PubMed: 22319200]
19. Chowdhury G, Shibata N, Yamazaki H, Guengerich FP. Cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analog of thalidomide. *Chem. Res. Toxicol.* 2014; 27:147–156. [PubMed: 24350712]
20. Mutoh S, Sobhany M, Moore R, Perera L, Pedersen L, Sueyoshi T, Negishi M. Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. *Sci. Signal.* 2013; 6:ra31. [PubMed: 23652203]

Figure 1.

Chemical structures of thalidomide, the primary rodent metabolite 5'-hydroxythalidomide (5'-OH-thalidomide), and the primate metabolite 5-hydroxythalidomide (5-OH-thalidomide).

Figure 2.

Effects of thalidomide and its metabolites on P450 3A- and 2B6-mediated drug oxidation activities in human hepatocytes and HepaRG cells. Human hepatocytes (A) and HepaRG cells (B-D) were cultured with thalidomide (1.0 mM) and its metabolites for 72 h. Control formation rates of midazolam 1- (filled bar) and 4- (hatched bar) hydroxylation in human hepatocytes were 0.08 and 8.0 nmol/h/10⁶ cells, respectively. Control formation rates of midazolam 1- (filled bar) and 4- (hatched bar) hydroxylation and 1' hydroxymidazolam O- (hatched) and N (filled) glucuronide formation in HepaRG cells were 0.01, 0.80, 0.01, and 0.005 nmol/h/10⁶ cells, respectively. Bupropione hydroxylation activity in the control HepaRG cells was 0.02 nmol/h/10⁶ cells. Columns and bars show means and SD values from triplicate determinations. *, p < 0.05.

Figure 3.

Effects of thalidomide and its metabolites on P450 3A and 2B6 mRNA levels in human hepatocytes and HepaRG cells. P450 mRNA levels were determined after 48 h treatment with thalidomide (Materials and Methods). Columns and bars show means and SD values for triplicate determinations. *, $p < 0.05$.

Figure 4. Compound-induced modulation of PXR (A) and CAR (B) interaction with coregulator proteins. Each row shows the ligand-mediated $\log_{10}$ -fold modulation of nuclear receptor binding (modulation index, MI) to each of the co-regulator motifs on the array. Significance of the modulation of each interaction is indicated (* $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$). (Dis)similarity between compounds or co regulator motifs, as determined by hierarchical clustering (Euclidean distance, average linkage) is summarized in the dendrograms. Red, positive response; blue, negative response. 5'-OH-thalidomide, 5' hydroxythalidomide; 5-OH-thalidomide, 5-hydroxythalidomide.